News
Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos
Kissei Pharmaceutical is reversing a recommendation related to Amgen-shared Tavneos that it made just a few days ago, now saying the rare disease drug can be given to new patients.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
The partnership framework agreement allows Moderna and U of T to collaborate across a broad variety of areas, ranging from molecular genetics to biomedical engineering, biochemistry and more.
GENFIT delivered on its promise to improve its financial situation in the year to December 31, 2021, posting an income of $40.8 million USD from a loss of $20.3 million in the year prior.
The new bills result from a three-year investigation that honed in on anti-competitive efforts that have prevented generic drugs and biosimilars from entering the market.
Janssen Pharmaceutical, under parent organization Johnson & Johnson, secured an arbitrary win this week that results in royalty decisions stemming from licensing and marketing of daratumumab.
COVID-19 has killed more than six million people worldwide and almost one million in the U.S. And the pandemic isn’t over yet. Read on for that and more updates about COVID-19.
GeoVax is conducting two Phase II COVID-19 vaccine clinical trials with its GEO-CMO4S1 vaccine. One of the trials is among immunocompromised patients.
In a regulatory filing, the Cambridge, Massachusetts-based company indicated that it plans to “refocus its strategic priorities” and lay off 42% of its workforce.
Janssen’s Phase II study of nipocalimab for generalized myasthenia gravis (gMG) shows that serum IgG levels can be used as a supportive biomarker to manage this disease.
Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week.
Six months after acquiring Kadmon Holdings, pharma giant Sanofi is closing Kadmon’s New York facility. As part of the paring down, Sanofi is also laying off 25 employees at the location.